Cantel Medical Completes Acquisition Of PuriCore International Ltd. Enhances Cantel's global leadership in automated endoscope reprocessing
LITTLE FALLS, N.J., July 1, 2014 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN), today announced that the company has successfully completed the acquisition of PuriCore International Limited., a wholly-owned subsidiary of PuriCore plc (LSE: PURI). The transaction further enhances Cantel Medical's global leadership of automated endoscope reprocessing and provides the company with additional resources and capabilities to execute on its broader international strategy. PuriCore International Limited will be renamed Cantel Medical (UK) Limited and will be reported as part of our Endoscopy segment.
PuriCore International Limited is a leading provider of automated endoscope reprocessors, endoscope drying and storage cabinets, chemistry and consumables in addition to comprehensive maintenance and validation services in the United Kingdom. With an employee base of approximately 120 individuals, including a complete sales and service team and facilities in Stafford and Clevedon, England, the addition of PuriCore International provides Cantel Medical comprehensive coverage of the UK market.
"This acquisition is an exciting step in the execution of our international strategy," said Jorgen Hansen, President of Medivators and COO of Cantel Medical. "The addition of the PuriCore endoscopy business to Medivators will meaningfully strengthen our offering in automated endoscope reprocessing while also enhancing our international capabilities and competitiveness. We are excited to welcome the entire PuriCore International workforce to the Cantel family, and we look forward to working together toward delivering infection prevention and control solutions to patients and customers worldwide."
About Cantel Medical Corp.
Cantel Medical is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives. Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products. For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
SOURCE Cantel Medical Corp.